The Potential for Tissue Targeted Complement Inhibition: Generation of a Novel Therapeutic Platform

Time: 9:30 am
day: Day Two


  • Targeted delivery of negative regulatory proteins potently inhibits complement activation and injury in diseased tissue without systemic blockade
  • Q32 Bio tissue targeted complement therapeutics biodistribute to diseased tissues and provide long-term durable tissue PK/PD and efficacy
  • Q32 Bio tissue targeted complement therapeutics have the potential to be used for a wide range of disease indications in which complement activation is implicated and systemic targeting is not feasible or desirable

Download the event guide here for full session details